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Abstract.
A series of phosphinegold(I) thionucleobase analogues, [R3PAu(SRX)] (R Et, Ph or c-
hexyl; HSR 2-mercaptobenzoic acid, HSR2 2-thiouracil, HSR3 6-mercaptopurine
and HSR4 6-thioguanine) have been examined for their in vitro cytotoxicity in L1210
murine leukemia cells in culture. The range of ID50 values (continuous 48 h exposure) for
the complexes is 0.041 0.131 IM. The complexes with SR3 and SR4 are generally the
most active; however, there is no clear trend associated with the phosphine ligands.
Introduction.
Transition metal complexes have proved to possess significant anticancer activity and there
are several reviews summarizing recent progress in this field. Most notable among these
complexes are those containing platinum, although other metal species, e.g. Ru(ll), Rh(ll),
Rh(lll) and Au(I), also show promising activity. Gold complexes have a long history in
medicine and several complexes are used in the treatment of rheumatoid arthritis at
present.2 Given the clinical success of Au(I) complexes it is not surprising that the
antitumor activity of some of these complexes has been investigated.3-5 The monomeric
species Auranofin, (1-thio-I-D-gluco-pyranose 2,3,4,6-tetraacetato-S)(triethyl-
phosphine)gold(I), an anti-arthritic drug, has been shown to possess maximum activity
against P388 leukemia;3 however, it was the bis-chelated diphosphine Au(I) complex,
[Au(Ph2P(CH2)2PPh2)2]+, that showed the most promising activity.5 Certain
phosphinegold(I) thiolates, i.e. containing the P-Au-S arrangement as in Auranofin, also
show encouraging activity4, 6 and the most notable among these is Ph3PAu(8-
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thiotheophyllinate).6 As an extension of previous studies of the anti-arthritic activity of
related complexes,7 the in vitro antitumor activity of a series of phosphinegold(I)
thiolates, where the thiolate ligand is derived from a thionucleobase, has been investigated
and the results of this study are reported herein. The antitumor activity of two of the
complexes has been reported previously in a conference abstract; however, to our
knowledge, no subsequent results have been published.8
Results and Discussion
Chemistry. The [R3PAu(SR’)] complexes have been prepared by the reaction of [R3PAuCI]
and the thionucleobase in the presence of KOH. The complexes have been characterized
spectroscopically and in the case of certain examples, using X-ray crystallographic
techniques.7,9 The colorless/off-white solids are obtained in good yields and are relatively
air- and light-stable; only the [Et3PAu(SR1)] complex proved too unstable for testing. The
thiolates chosen for this study, shown below, are the deprotonated forms of 2-
mercaptobenzoic acid (HSR1), 2-thiouracil (HSR2), 6-mercaptopurine (HSR3) and 6-
thioguanine (HSR4); the R groups bound to the phosphine ligands are Et, Ph or c-hexyl.
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Crystal structure determinations on the complexes have revealed the presence of a linear
P-Au-S arrangement and a thiolate ligand (rather than a thione) in each case; an
illustration of the molecular structure of a representative compound, i.e. [Ph3PAu(SR3)],
as determined by X-ray diffraction methods is shown in Figure 1.7b
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Figure 1 The molecular structure of [Ph3PAu(SR3)].7b
Biological Testing. The results of growth inhibition testing of the phosphinegold(I)
thionucleobase complexes against murine L1210 leukemia cells in culture are summarized
in Table 1. It is noteworthy that the presence of gold in the complexes generally results in
higher activity than that exhibited by the free thionucleobases, two of which possess
significant antitumor activity- 6-mercaptopurine (HSR3) and 6-thioguanine (HSR4) are
used clinically for the treatment of leukemia.10 The complexes of HSR3 resulted in at least
three-fold greater activity, although the addition of gold to 6-thioguanine did not increase
significantly its growth inhibitory properties. For the 2-mercaptobenzoic acid (HSR 1) and
2-thiouracil (HSR2) derivatives, the activity was enhanced by at least two to three orders
of magnitude, pointing to the critical role of Au(I). The only metal-containing anticancer
drugs in common use are cisplatin and carboplatin; for comparison, their ID50’s against
L1210 are approximately 0.6 and 12 IM, respectively.
An examination of the ID50 values in Table reveals that no simple structure/activity
relationship exists between the nature of the phosphine ligand and the in vitro activity
against the L1210 murine leukemia. In fact, there is no significant difference in activity
among the complexes within any one group. Nevertheless, all of the compounds are at least
as active as 6-thioguanine, and represent a potentially exciting new class of antitumor
agent. Further work is underway to determine the range of activity in other tumor types,
and to investigate the mechanism of action.
301Vol. 1, No. 4, 1994 In vitroAnfftumourActivity ofSome Trlorganophosphinegold(l) Thtonucleobases
Table 1. Biological Activity of the Thiols (HSRx) and the Phosphinegold(I) Thiolates
([R3PAu(SRX)]) a
Thiols HSR HSR2 HSR3 HSR4
> 20 > 1.00 0.31 0+0.133 0.096+0.022
Complexes SR1 SR2 SR3 SR4
R Et 0.086+0.082 0.094_+0.051 0.041+0.013
R Ph 0.047+0.005 0.131 _+0.072 0.083+_0.048
R c-hexyl 0.082+0.022 0.115+0.020 0.079+0.028
0.052+_0.017
0.084_+0.030
a Values quoted are ID5o (M) and represent the dose of compound causing 50% growth
inhibition of L1210 mouse leukemia cells in culture after 48 h exposure to the compound.
Results are expressed as mean _+. standard deviation of three to five replicates.
Experimental Section
(a) Syntheses.
papers.7,9
The complexes and their characterization are as reported in earlier
(b) Biological Testing. L1210 mouse leukemia cells were grown as suspension cultures in
Eagle’s minimum essential medium plus 1% glutamine and 10% fetal calf serum (Flow
Laboratories). The compounds were dissolved in DMSO at 10 concentrations over a 3-log
range, with a final maximum DMSO concentration in the medium of 0.5%. Growth
inhibition was tested by incubation of log-phase cells at 37C in a humidified incubator
gassed with 10% CO2/90% air for 48 h in the presence of the compound. Cells were then
counted using a Coulter counter, and the ID50 in pM, or dose causing 50% inhibition of cell
growth, was determined from the curve of percentage growth versus dose. All assays were
performed at least in triplicate. Control cultures exposed only to the vehicle were the
reference for 100% growth in each test.
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